By Thomas Anderson and Rotem Petranker — 2018
There is a growing research literature suggesting psychedelics hold incredible promise for treating mental health ailments ranging from depression and anxiety to PTSD. But how do we know for sure?
Read on theconversation.com
CLEAR ALL
Psychedelic drugs like psilocybin are being tested to treat mental illness. They're also expanding our understanding about human consciousness.
1
People of color are dealing with racism all the time, in large and small ways, and even dealing with racism in healthcare, even dealing with racism in therapy.
While we can now begin to glimpse an end to the drug war, it is much harder to envision what the drug peace will look like. How will we fold these powerful substances into our society and our lives so as to minimize their risks and use them most constructively?
After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction.
2
The last time I was on ketamine, I was hooked up to an IV following surgery. This time, the drug—in general medical use as an anesthetic since 1970—arrived on my doorstep courtesy of Mindbloom, a new telemedicine company specializing in ketamine-based psychedelic therapy.
Research into psychedelics, shut down for decades, is now yielding exciting results.
Now, as a handful of patients and more recently doctors and therapists have been granted exemptions to use psilocybin, the nation’s federal health agency is considering making changes to existing policies that could open the door to much more than magic mushrooms.
Williams is the co-lead author of a recent retrospective study that found those who tried doses of psilocybin (more commonly known as magic mushrooms), LSD, or MDMA (the pure substance found in Ecstasy or Molly) reported a decrease in trauma symptoms, depression and anxiety after 30 days.
Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
Psychedelic drugs—once promising research subjects that were decades ago relegated to illicit experimentation in dorm rooms—have been steadily making their way back into the lab for a revamped 21st-century-style look.